Genetic vasopressin 1b receptor variance in overweight and diabetes mellitus

European Journal of Endocrinology

Volumn 174, Issue 1, 2016, Pages 69-75

  Enhörning, Sofia ^a   Sjögren, Marketa ^a   Hedblad, Bo ^a   Nilsson, Peter M ^a   Struck, Joachim ^b   Melander, Olle ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SPHINGOTEC GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COPEPTIN; VASOPRESSIN V1B RECEPTOR; GLYCOPEPTIDE; VASOPRESSIN RECEPTOR;

ADULT; AGE DISTRIBUTION; ALLELE; ANTHROPOMETRIC PARAMETERS; ARTICLE; AVPR1B GENE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR PARAMETERS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; OBESITY; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST CIRCUMFERENCE; ABDOMINAL OBESITY; AGED; BLOOD; GENETIC VARIATION; GENETICS; MIDDLE AGED; SWEDEN;

AGED; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS; FEMALE; GENETIC VARIATION; GENOTYPE; GLYCOPEPTIDES; HUMANS; MALE; MIDDLE AGED; OBESITY; OBESITY, ABDOMINAL; OVERWEIGHT; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECEPTORS, VASOPRESSIN; SWEDEN;

EID: 84956839850     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-0781     Document Type: Article

References (35)

1. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottir A, Styrkarsdottir U, Gretarsdottir S, Thorlacius S, Jonsdottir I et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nature Genetics 2009 41 18-24. (doi:10.1038/ng.274)
2. Russo P, Lauria F & Siani A. Heritability of body weight:moving beyond genetics. Nutrition, Metabolism, and Cardiovascular Diseases 2010 20 691-697. (doi:10.1016/j.numecd.2010.09.007)
3. Chan JM, Rimm EB, Colditz GA, Stampfer MJ &Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994 17 961-969. (doi:10.2337/diacare.17.9.961)
4. Lolait SJ, O'Carroll AM, McBride OW, Konig M, Morel A & Brownstein MJ. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992 357 336-339. (doi:10.1038/357336a0)
5. Filep J & Rosenkranz B. Mechanism of vasopressin-induced platelet aggregation. Thrombosis Research 1987 45 7-15. (doi:10.1016/0049-3848(87)90252-0)
6. Ohlstein EH & Berkowitz BA. Human vascular vasopressin receptors: Analysis with selective vasopressin receptor antagonists. Journal of Pharmacology and Experimental Therapeutics 1986 239 737-741.
7. Whitton PD, Rodrigues LM & Hems DA. Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochemical Journal 1978 176 893-898. (doi:10.1042/bj1760893)
8. Keppens S & de Wulf H. The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis. Biochimica et Biophysica Acta 1979 588 63-69. (doi:10.1016/0304-4165(79)90371-4)
9. Holmes CL, Landry DW & Granton JT. Science review: Vasopressin and the cardiovascular system part 1 -receptor physiology. Critical Care 2003 7 427-434. (doi:10.1186/cc2337)
10. Abu-Basha EA, Yibchok-Anun S & Hsu WH. Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism: Clinical and Experimental 2002 51 1184-1190. (doi:10.1053/meta.2002.34052)
11. Morgenthaler NG, Struck J, Alonso C & Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clinical Chemistry 2006 52 112-119. (doi:10.1373/ clinchem.2005.060038)
12. Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010 121 2102-2108. (doi:10.1161/CIRCULATIONAHA.109.909663)
13. Enhorning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM & Melander O. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: The prospective Malmo Diet and Cancer Study cardiovascular cohort. International Journal of Obesity 2013 37 598-603. (doi:10.1038/ ijo.2012.88)
14. Enhorning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler NG & Melander O. Plasma copeptin, a unifying factor behind the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 2011 96 E1065-E1072. (doi:10.1210/jc.2010-2981)
15. Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH Jr & Kullo IJ. Plasma carboxy-Terminal provasopressin (copeptin): A novel marker of insulin resistance and metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 2009 94 2558-2564. (doi:10.1210/jc.2008-2278)
16. Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort RT, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 2012 55 1963-1970. (doi:10.1007/s00125-012-2545-x)
17. Aoyagi T, Birumachi J, HiroyamaM, Fujiwara Y, Sanbe A, Yamauchi J & Tanoue A. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology 2007 148 2075-2084. (doi:10.1210/en.2006-1315)
18. Hiroyama M, Aoyagi T, Fujiwara Y, Birumachi J, Shigematsu Y, Kiwaki K, Tasaki R, Endo F & Tanoue A. Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Molecular Endocrinology 2007 21 247-258. (doi:10.1210/me.2006-0069)
19. Enhorning S, Leosdottir M, Wallstrom P, Gullberg B, Berglund G, Wirfalt E & Melander O. Relation between human vasopressin 1a gene variance, fat intake, and diabetes. American Journal of Clinical Nutrition 2009 89 400-406. (doi:10.3945/ajcn.2008.26382)
20. Masuki S, Mori M, Tabara Y, Miki T, Sakurai A, Morikawa M, Miyagawa K, Higuchi K & Nose H. Vasopressin V1a receptor polymorphism and interval walking training effects in middle-Aged and older people. Hypertension 2010 55 747-754. (doi:10.1161/HYPERTENSIONAHA. 109.147728)
21. Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA, Mori T & Tsujimoto G. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-Adrenal axis activity under both stress and resting conditions. Journal of Clinical Investigation 2004 113 302-309. (doi:10.1172/JCI200419656)
22. Fujiwara Y, Hiroyama M, Sanbe A, Aoyagi T, Birumachi J, Yamauchi J, Tsujimoto G & Tanoue A. Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. Journal of Physiology 2007 584 235-244. (doi:10.1113/jphysiol.2007.136481)
23. Berglund G, Elmstahl S, Janzon L & Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. Journal of Internal Medicine 1993 233 45-51. (doi:10.1111/j.1365-2796.1993.tb00647.x)
24. Li C, Engstrom G, Hedblad B, Berglund G & Janzon L. Blood pressure control and risk of stroke: A population-based prospective cohort study. Stroke 2005 36 725-730. (doi:10.1161/01.STR.0000158925.12740.87)
25. Persson M, Hedblad B, Nelson JJ & Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-Aged nondiabetic subjects. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1411-1416. (doi:10.1161/ATVBAHA.107.142679)
26. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM & Gudbjornsdottir S. Risk prediction of cardiovascular disease in type 2 diabetes: A risk equation from the Swedish National Diabetes Register. Diabetes Care 2008 31 2038-2043. (doi:10.2337/dc08-0662)
27. Lindholm E, Agardh E, Tuomi T, Groop L & Agardh CD. Classifying diabetes according to the new WHO clinical stages. European Journal of Epidemiology 2001 17 983-989. (doi:10.1023/A:1020036805655)
28. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M & Olausson PO. External review and validation of the Swedish national inpatient register. BMC Public Health 2011 11 450. (doi:10.1186/1471-2458-11-450)
29. A finger on the pulse. Monitoring public health and social conditions in Sweden 1992-2002. National Board of Health and Welfare, Stockholm, 2003. (The report can be downloaded from http://www.socialstyrelsen. se/publikationer2003/2003-118-16).
30. Wettermark B, Hammar N, Fored CM, Leimanis A, OtterbladOlausson P, Bergman U, Persson I, Sundstrom A, Westerholm B & Rosen M. The new Swedish Prescribed Drug Register -opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiology and Drug Safety 2007 16 726-735. (doi:10.1002/pds.1294)
31. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P & Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes. New England Journal of Medicine 2008 359 2220-2232. (doi:10.1056/ NEJMoa0801869)
32. Fenske W, Wanner C, Allolio B, Drechsler C, Blouin K, Lilienthal J & Krane V. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. Journal of the American Society of Nephrology 2011 22 782-790. (doi:10.1681/ASN.2010070691)
33. McGuigan FE & Ralston SH. Single nucleotide polymorphism detection: Allelic discrimination using TaqMan. Psychiatric Genetics 2002 12 133-136. (doi:10.1097/00041444-200209000-00003)
34. Rabadan-Diehl C & Aguilera G. Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C. Endocrinology 1998 139 3220-3226. (doi:10.1210/endo.139.7.6121)
35. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A & Mikhailidis DP. Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis. Journal of Clinical Endocrinology and Metabolism 2009 94 2692-2701. (doi:10.1210/jc.2009-0370)